Galera Therapeutics Inc (NASDAQ: GRTX) Has Another Chance To Impress You

Currently, there are 54.39M common shares owned by the public and among those 38.25M shares have been available to trade.

The company’s stock has a 5-day price change of -28.97% and 16.22% over the past three months. GRTX shares are trading 14.31% year to date (YTD), with the 12-month market performance down to -93.80% lower. It has a 12-month low price of $0.09 and touched a high of $3.59 over the same period. GRTX has an average intraday trading volume of 2.10 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -24.32%, -16.88%, and -76.06% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Galera Therapeutics Inc (NASDAQ: GRTX) shares accounts for 14.87% of the company’s 54.39M shares outstanding.

It has a market capitalization of $9.04M and a beta (3y monthly) value of 2.17. The earnings-per-share (ttm) stands at -$1.42. Price movements for the stock have been influenced by the stock’s volatility, which stands at 28.42% over the week and 14.21% over the month.

Analysts forecast that Galera Therapeutics Inc (GRTX) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2024. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.58 a year ago. EPS should grow at an annualized rate of 34.40% over the next five years, compared to -2.39% over the past 5-year period.

Looking at the support for the GRTX, a number of firms have released research notes about the stock. Piper Sandler stated their Neutral rating for the stock in a research note on August 10, 2023, with the firm’s price target at $6-$0.50. BofA Securities was of a view on October 19, 2021 that the stock is Underperform, while Credit Suisse gave the stock Outperform rating on April 26, 2021, issuing a price target of $15. Credit Suisse on their part issued Outperform rating on December 16, 2020.

Most Popular

Related Posts